4.7 Article

Synergistic disruption of BTK and BCL-2 causes apoptosis while inducing ferroptosis in double-hit lymphoma

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Oncology

Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse Large B-cell Lymphoma

Julie Devin et al.

Summary: Diffuse large B-cell lymphoma (DLBCL) is a common hematological malignancy, and alterations in iron metabolism may be targeted for therapy. Iron score (IS), a gene expression-based risk score, can identify high-risk DLBCL patients who may benefit from targeting iron homeostasis. Ironomycin, a potential treatment for DLBCL, inhibits cell proliferation and induces cell death.

CANCER RESEARCH (2022)

Article Hematology

Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma

Haiyan Yang et al.

Summary: BTK inhibitors, such as zanubrutinib, have shown modest antitumor activity in non-GCB DLBCL, with potential efficacy in patients with CD79B and MYD88 mutations.

BLOOD ADVANCES (2022)

Review Cell Biology

Ferroptosis: A New Promising Target for Lung Cancer Therapy

Rui Xiong et al.

Summary: Ferroptosis is a new type of regulatory cell death that is caused by the accumulation of iron and lipid peroxides. It has been shown to play a crucial role in tumor progression, especially in lung cancer. Inducing ferroptosis in cells can inhibit tumor cell growth and potentially reverse tumorigenesis.

OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2021)

Article Oncology

Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication

Pin Lu et al.

Summary: Ibrutinib and venetoclax are effective as monotherapy for CLL, with better results when used in combination. They target different subpopulations within CLL and effectively reduce both subpopulations. Using a proliferation model may help identify novel drug combinations for eradicating residual disease.

BLOOD CANCER JOURNAL (2021)

Article Hematology

Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma

Zhiyuan Zhou et al.

Summary: The study demonstrates that the combination therapy of ibrutinib and the BCL2 inhibitor venetoclax shows promising efficacy and synergistic effects in patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) who have non-GCB subtype and BCL2 overexpression, with well-tolerated toxicities.

ANNALS OF HEMATOLOGY (2021)

Article Oncology

High-Grade B-Cell Lymphoma (HGBL) with MYC and BCL2 and/or BCL6 Rearrangements Is Predominantly BCL6-Rearranged and BCL6-Expressing in Taiwan

Cheng-Chih Tsai et al.

Summary: This study compared the epidemiological, cytogenetic, and clinical differences between patients with multiple hit diffuse large B-cell lymphoma in Taiwan and those in western countries. The majority of patients in Taiwan harbor a BCL6 rearrangement, suggesting the need for mandatory screening for BCL6 rearrangement in aggressive HGBL patients in Taiwan. Contrary to data from western countries, a significant proportion of patients in Taiwan with DH/TH-HGBL have BCL6 rearrangement.

CANCERS (2021)

Article Oncology

Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia A Nonrandomized Phase 2 Trial

Nitin Jain et al.

Summary: The combination therapy of ibrutinib and venetoclax showed promising results in achieving bone marrow U-MRD remission in previously untreated patients with CLL. The durability of remissions was observed over a follow-up period of more than 3 years, with high response rates across different high-risk disease subgroups, including patients with del(17p)/TP53-mutated CLL.

JAMA ONCOLOGY (2021)

Article Oncology

Overcoming Acquired Epigenetic Resistance to BTK Inhibitors

Arthur L. Shaffer et al.

Summary: The study found that resistance to BTK inhibitors in some lymphoid malignancies is primarily due to epigenetic changes rather than genetic alterations. They also observed this resistance mechanism in chronic lymphocytic leukemia, suggesting that epigenetic alterations may play a greater role in BTK inhibitor resistance than currently believed.

BLOOD CANCER DISCOVERY (2021)

Review Hematology

The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma

Yang Xia et al.

ACTA HAEMATOLOGICA (2020)

Article Oncology

Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on

Stefano Molica et al.

HEMATOLOGICAL ONCOLOGY (2020)

Article Cell Biology

The Senolytic Drug Navitoclax (ABT-263) Causes Trabecular Bone Loss and Impaired Osteoprogenitor Function in Aged Mice

Anuj K. Sharma et al.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)

Article Biochemistry & Molecular Biology

SynergyFinder 2.0: visual analytics of multi-drug combination synergies

Aleksandr Ianevski et al.

NUCLEIC ACIDS RESEARCH (2020)

Review Oncology

Emerging therapies in mantle cell lymphoma

Walter Hanel et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

Review Oncology

Ibrutinib in B-cell lymphoma: single fighter might be enough?

Chao Xue et al.

CANCER CELL INTERNATIONAL (2020)

Article Medicine, General & Internal

Ibrutinib and Venetoclax for First-Line Treatment of CLL

Nitin Jain et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Review Oncology

Inhibiting Bruton's Tyrosine Kinase in CLL and Other B-Cell Malignancies

Fabienne Lucas et al.

TARGETED ONCOLOGY (2019)

Review Oncology

Targeting BTK in CLL: Beyond Ibrutinib

David A. Bond et al.

CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2019)

Article Oncology

Double-hit lymphoma: So what?

Andrew Davies

HEMATOLOGICAL ONCOLOGY (2019)

Review Oncology

BCL-2 Inhibitors, Present and Future

Christine E. Ryan et al.

CANCER JOURNAL (2019)

Review Biochemistry & Molecular Biology

Apoptosis: A Target for Anticancer Therapy

Claire M. Pfeffer et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)

Article Medicine, Research & Experimental

Glutathione peroxidase 4 overexpression inhibits ROS-induced cell death in diffuse large B-cell lymphoma

Yuko Kinowaki et al.

LABORATORY INVESTIGATION (2018)

Review Biochemistry & Molecular Biology

Role of Bruton's tyrosine kinase in B cells and malignancies

Simar Pal Singh et al.

MOLECULAR CANCER (2018)

Article Physiology

Heme oxygenase-1 mitigates ferroptosis in renal proximal tubule cells

Oreoluwa Adedoyin et al.

AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2018)

Review Hematology

How I treat double-hit lymphoma

Jonathan W. Friedberg

Article Oncology

Heme oxygenase-1 accelerates erastin-induced ferroptotic cell death

Min-Young Kwon et al.

ONCOTARGET (2015)

Article Biochemistry & Molecular Biology

Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model

Bhagwan Yadav et al.

COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2015)

Article Biology

Trypan blue exclusion assay by flow cytometry

B. A. Avelar-Freitas et al.

BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH (2014)

Article Biochemistry & Molecular Biology

Regulation of Ferroptotic Cancer Cell Death by GPX4

Wan Seok Yang et al.

Article Chemistry, Multidisciplinary

Ferrostatins Inhibit Oxidative Lipid Damage and Cell Death in Diverse Disease Models

Rachid Skouta et al.

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2014)

Article Medicine, General & Internal

Stromal Gene Signatures in Large-B-Cell Lymphomas

G. Lenz et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Article Medicine, General & Internal

A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling

Michael Hummel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2006)